drugset
drugset / Trial / NCT05841134

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

NCT05841134 ↗

Phase 2 Not yet recruiting 25 enrolled The First Affiliated Hospital of Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.

Timeline

Start
2023-06-01
Primary completion
2024-12-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

colorectal cancer